Oncology and Hematology - Prova Education

Episodes 1-16 of 115

MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
0.50 credits 5 episodes
- Kathleen Moore, MD, MS
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
MOA: CDH6-Targeted Antibody-Drug Conjugates
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
0.50 program credits
- Joyce F. Liu, MD, MPH
- Kathleen Moore, MD, MS
0.50 program credits
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 6 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 6 episodes
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
MinuteCE®
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
MinuteCE®
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
1.00 credit 10 episodes
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 credit 10 episodes
Why CELMoDs Matter in Myeloma
Why CELMoDs Matter in Myeloma
MinuteCE®
Why CELMoDs Matter in Myeloma
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Data Dive: Clinical Evidence Behind CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
MinuteCE®
Data Dive: Clinical Evidence Behind CELMoDs
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit

Prev
1
2
3
…
7
8
Next

1/6